GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » Price-to-Owner-Earnings

Denali Therapeutics (Denali Therapeutics) Price-to-Owner-Earnings : (As of May. 11, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Denali Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-11), Denali Therapeutics's share price is $18.31. Denali Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Denali Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 9 years, the highest Price-to-Owner-Earnings of Denali Therapeutics was 28.59. The lowest was 17.87. And the median was 20.25.


DNLI's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.03
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-11), Denali Therapeutics's share price is $18.31. Denali Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.96. Therefore, Denali Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-11), Denali Therapeutics's share price is $18.31. Denali Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.06. Therefore, Denali Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 9 years, Denali Therapeutics's highest PE Ratio without NRI was 393.00. The lowest was 0.00. And the median was 263.12.


Denali Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Denali Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Price-to-Owner-Earnings Chart

Denali Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Denali Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Denali Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Denali Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Denali Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's Price-to-Owner-Earnings falls into.



Denali Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Denali Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=18.31/-3.13
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Denali Therapeutics  (NAS:DNLI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Denali Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Denali Therapeutics (Denali Therapeutics) Business Description

Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Executives
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Carole Ho officer: Chief Medical Officer C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Ryan J. Watts director, officer: President and CEO C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes officer: CFO and Treasurer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Alexander O. Schuth officer: COO and Secretary C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne director 1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris director 60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton 10 percent owner 201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Denali Therapeutics (Denali Therapeutics) Headlines

From GuruFocus